AU Patent

AU2018203021B2 — Bromocriptine formulations

Assigned to Veroscience LLC · Expires 2020-02-06 · 6y expired

What this patent protects

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

USPTO Abstract

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018203021B2
Jurisdiction
AU
Classification
—
Expires
2020-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Veroscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.